- Pioneering GPS-enabled location device developer MetAlert is building on two decades of experience with new products designed to broaden its suite of technology for remote patient monitoring (“RPM”) in an unobtrusive manner plus monitoring seniors for falls
- MetAlert recently announced that it has engaged the financial strategy advisory firm Joseph Gunnar & Co., LLC to help direct its decisions ranging from acquisitions to potential up listing on a national exchange
- The company’s products include its flagship patented shoe insole device enabled with GPS, Bluetooth, and Wi-Fi functionality for tracking seniors or people with autism prone to wandering and getting lost, as well as protecting potential kidnapping targets
- MetAlert’s latest product developments provide artificial intelligence as an accessory to identify fall risks and provide related analysis of patients’ physical functioning, while allowing the patient to maintain a degree of privacy and independence
Medical patient location device developer MetAlert (OTC: MLRT) is launching a suite of wearable companion products to its innovative SmartSole shoe insole units and, on the heels of rebranding the company to better represent its strategic direction, recently announced that it has engaged financial advisory firm Joseph Gunnar & Co., LLC to guide its financing and acquisition decisions.
“MetAlert is approaching the inflection point of its growth curve by its ability to sell a multitude of products and services to a broader audience, which will result in greater revenue per user (“RPU”),” MetAlert CEO Patrick Bertagna stated (https://ibn.fm/0eYGw). “We are thrilled to align with…
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
